Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.63 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.63 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8710367 | 1.00 | ADORA1 (0.63) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL3263501 | 0.91 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL4133072 | 0.91 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL4451881 | 0.91 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL4144916 | 0.91 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8704620 | 0.89 | ADORA1 (0.81) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8706048 | 0.87 | ADORA1 (0.59) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8709754 | 0.86 | ADORA1 (0.83) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL4131261 | 0.86 | ADORA1 (0.64) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL8706053 | 0.86 | ADORA1 (0.64) | ADORA1ADORA2AADORA2BADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253665-A1 | METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR | OTSUKI LAUREN | 2009-10-08 | — | — | US | claimed |
| EP-2087888-A1 | Adenosine a1 receptor antagonists for the treatment of alkalosis | Novacardia, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20070238672-A1 | CO-ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS AND ANTICONVULSANTS | NOVACARDIA, INC. | 2007-10-11 | — | — | US | claimed |
| US-20050239759-A1 | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor | NOVACARDIA, INC. | 2005-10-27 | — | — | US | claimed |
| US-20040229901-A1 | Method of treatment of disease using an adenosine A1 receptor antagonist | NOVACARDIA, INC. | 2004-11-18 | — | — | US | claimed |
| EP-0619316-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-08-12 | — | — | EP | claimed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | claimed |
| US-20090253665-A1 | METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR | OTSUKI LAUREN | 2009-10-08 | — | — | US | disclosed |
| US-7579331-B2 | Method of improved diuresis in individuals with impaired renal function | NOVACARDIA, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-2087888-A1 | Adenosine a1 receptor antagonists for the treatment of alkalosis | Novacardia, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090197900-A1 | METHODS OF TREATING HEART FAILURE AND RENAL DYSFUNCTION IN INDIVIDUALS WITH AN ADENOSINE A1 RECEPTOR ANTAGONIST | DITTRICH HOWARD | 2009-08-06 | — | — | US | disclosed |
| US-20080242684-A1 | METHODS OF ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS | NOVACARDIA, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | MUGERDITICHIAN MARK | 2008-03-20 | — | — | US | disclosed |
| US-20060035911-A1 | Method of improved diuresis in individuals with impaired renal function | WIDDER KENNETH J | 2006-02-16 | — | — | US | disclosed |
| US-20060030572-A1 | Method of improved diuresis in individuals with impaired renal function | WIDDER KENNETH J | 2006-02-09 | — | — | US | disclosed |
| US-20050004145-A1 | Method of improved diuresis in individuals with impaired renal function | NOVACARDIA, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040229901-A1 | Method of treatment of disease using an adenosine A1 receptor antagonist | NOVACARDIA, INC. | 2004-11-18 | — | — | US | disclosed |
| EP-0619316-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-08-12 | — | — | EP | disclosed |
| EP-0711772-A1 | PROCESS FOR PRODUCING XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229901-A1 | Method of treatment of disease using an adenosine A1 receptor antagonist | ADORA1, AGTR1, ADORA2A | ADORA1 1/4885ADORA2A 3/4885ADORA2B 4/4885 |
| US-20080242684-A1 | METHODS OF ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20050004145-A1 | Method of improved diuresis in individuals with impaired renal function | REN, ADORA2A, ATP6V1B1 | ADORA1 9/4885ADORA2A 2/4885ADORA2B 11/4885 |
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | DCX, FLT4, KDR | ADORA1 637/4885ADORA2A 98/4885ADORA2B 302/4885 |
| US-20070238672-A1 | CO-ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS AND ANTICONVULSANTS | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 4/4885 |
| US-20090197900-A1 | METHODS OF TREATING HEART FAILURE AND RENAL DYSFUNCTION IN INDIVIDUALS WITH AN ADENOSINE A1 RECEPTOR ANTAGONIST | ADORA1, NPPA, ADORA2A | ADORA1 1/4885ADORA2A 3/4885ADORA2B 6/4885 |
| US-20060030572-A1 | Method of improved diuresis in individuals with impaired renal function | REN, ADORA2A, ATP6V1B1 | ADORA1 9/4885ADORA2A 2/4885ADORA2B 11/4885 |
| US-20050239759-A1 | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor | ADORA1, ADORA2A, ADRA1A | ADORA1 1/4885ADORA2A 2/4885ADORA2B 5/4885 |
| US-20090253665-A1 | METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR | ADORA1, ADORA2A, ADRA1A | ADORA1 1/4885ADORA2A 2/4885ADORA2B 5/4885 |
| US-20060035911-A1 | Method of improved diuresis in individuals with impaired renal function | REN, ADORA2A, ATP6V1B1 | ADORA1 9/4885ADORA2A 2/4885ADORA2B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.